Clinakos

Day 3 at Piper Sandler Healthcare conference

Clinakos, Integrated Patient Data, Medically Smart AI, Rare diseases, Piper Sandler

As we dive into Day 3 of the Piper Sandler Healthcare Conference today, our team at Clinakos Inc. was excited with the vibrant discussions and transformative ideas shaping the future of cell therapy for oncology.

One such discussion yesterday was an important discussion on “The Preview of American Society of Hematology”. Dr. Jae Park of Memorial Sloan Kettering Cancer Center and Ran Reshef of Columbia University Cancer Center joined the discussion.

The discussion focused on the centralized model for cell therapy services, emphasizing the efficiency of a single program handling various indications, including blood cancer and solid tumors. Key bottlenecks include hospital bed availability and apheresis unit capacity. Outpatient care is increasing, with 70-80% of cell infusions done inpatient and 30% outpatient. The biggest unmet needs are side effect profiles and access to care. Delayed neurotoxicity, particularly with BCMA-targeted therapies, remains a concern. The conversation also touched on the potential of new products, which could offer faster manufacturing and lower neurotoxicity rates.

Some key themes from the conference so far:
🌟 The Power of Collaboration: Innovative partnerships are breaking barriers in drug development and patient care.
🌟 AI in Action: From diagnostics to drug discovery, AI’s role in accelerating timelines and improving outcomes continues to grow.
🌟 Focus on Patient-Centricity: Patient voices remain at the forefront, emphasizing the importance of understanding real-world challenges.

It’s been an incredible opportunity to exchange insights with leaders across the healthcare and life sciences spectrum. Excited for what the rest of the conference will bring!

What’s been your biggest takeaway from Piper Sandler so far? Let’s keep the conversation going!

Scroll to Top

Connect with us